Medicine
Procysbi 75 mg delayed-release capsule
Procysbi 75 mg delayed-release capsule is a prescription medicine containing Cysteamine for oral use, marketed by Horizon Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Prior to dispensing, store PROCYSBI delayed-release capsules and PROCYSBI…
Key facts
- Active ingredient (INN)
- Cysteamine
- Brand
- Procysbi
- Strength
- 75 mg
- Dosage form
- Delayed-release capsule
- Route
- Oral
- Packs
- 250 capsules
- Marketing authorisation holder
- Horizon Therapeutics
- Manufacturer
- Horizon Therapeutics
- Origin register
- US FDA, United States
- Storage
- Prior to dispensing, store PROCYSBI delayed-release capsules and PROCYSBI delayed-release oral granules in a refrigerator, 2°C to 8°C (36°F to 46°F). Protect from light and moisture.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A16AA04 Mercaptamine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 30 April 2013
- Identifiers
- RxCUI 1421467, 1421473, 1421475 +5DailyMed set ID d3a3ec28-f746-463a-bb92-3bc8826db09eNDC 75987-101Application NDA203389
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 250 capsule, delayed release pellets in 1 bottle | 75987-101-08 | Horizon Therapeutics | 30 April 2013 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 15 August 1994 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Cysteamine
Clinical summary
Cysteamine is a cystine depleting agent indicated for the management of nephropathic cystinosis in children and adults. It is available as ophthalmic solution, capsules and delayed-release capsules for oral use. MedsAcross supplies Cysteamine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about CysteamineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Cystagon prescribing information (Mylan Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Procysbi 75 mg delayed-release capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.